Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Research seminar, 17 March 2020: Zoonotic Antimicrobial Resistance

Antimicrobial resistance is one of the biggest threats to health. Over time, bacteria can develop an ability to resist medicinal substances such as antibiotics that are used in the treatment of infectious diseases. Fortunately, the situation is tolerable in Finland and other Nordic countries.The research seminar will be held in Lecture Hall C111 at Mustialankatu 3, Viikki, Helsinki,on Tuesday 17 September 2020 from 3 to 4 pm.The seminar is open to everyone, and no advance registration is required. The research seminar can be followed via Skype using the link 52289477@193.166.18.22.

Norwegian Energy Company ASA - Share buyback programme - increase in volume

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.  Oslo, 9 March 2020: Reference is made to the stock exchange release of 27 February 2020 in which Norwegian Energy Company ASA ("Noreco" or the "Company") initiated a share buyback programme of up to 160,000 own shares. Due to limited traded volume, the maximum number of shares that may be acquired during any trading day is

Hamlet Pharma has been granted M2.2€ from Horizon 2020

We are proud to announce that Hamlet Pharma has been granted 2.2 million Euros from the EIC Accelerator fund from Horizon 2020. The EIC Accelerator fund supports innovation within the EU to develop and bring to market new products, services and business models that will drive economic growth.The grant is awarded for the application entitled ‘Alpha1H - A Unique Bladder Cancer Therapeutic, Acting with Great Precision’ and has a duration of 24 months. The grant will be paid in parts during the project's duration and will specifically support further clinical trials as well as the next steps in

Short delay in the clinical phase II study

Scandion Oncology A/S (“Scandion Oncology”) informs about a short delay in the clinical phase II study with SCO-101 in drug resistant colorectal cancer. The delay is due to external events outside the influence of Scandion Oncology and is unrelated to the treatment with SCO-101.CEO Nils Brunner comments “At Scandion Oncology we are doing everything possible to secure that this delay will be as short as possible. We expect study activities to be back on track within the next few weeks and we are exploring solutions to keep the preset timelines”. For further information regarding

Distribution and listing of Electrolux Professional AB (publ)

On February 21, 2020 the Extraordinary General Meeting of AB Electrolux (publ) (“Electrolux”) decided to distribute all shares in the wholly-owned subsidiary Electrolux Professional AB (publ) (“Electrolux Professional”) to the shareholders of Electrolux. The Board of Director’s were at the same time authorized to determine the record date for the distribution. The record date has now been set to March 19, 2020.All shares in the wholly owned subsidiary Electrolux Professional will be distributed, whereby one (1) share of series A in Electrolux will entitle to one (1) share of series A in

Distribution and listing of Electrolux Professional AB (publ)

On February 21, 2020 the Extraordinary General Meeting of AB Electrolux (publ) (“Electrolux”) decided to distribute all shares in the wholly-owned subsidiary Electrolux Professional AB (publ) (“Electrolux Professional”) to the shareholders of Electrolux. The Board of Director’s were at the same time authorized to determine the record date for the distribution. The record date has now been set to March 19, 2020.All shares in the wholly owned subsidiary Electrolux Professional will be distributed, whereby one (1) share of series A in Electrolux will entitle to one (1) share of series A in

Össur hf: Candidates to the Board of Directors

Announcement no. 19/2020 9 March 2020  Candidates to the Board of Directors Enclosed are details on the candidates to the Board of Directors of Össur hf., to be elected at the Annual General Meeting held on Thursday, 12 March 2020, at 9:00 am (GMT) at Össur's offices at Grjótháls 5, Reykjavik, Iceland. Further information  David Hreidarsson, Investor Relations, dhreidarsson@ossur.com, +354 661 8225 Helga Danielsdottir, Investor Relations, hdanielsdottir@ossur.com, +354 766 4959 Össur press releases by e-mail  If you wish to receive Össur press releases by e-mail

Nanoform and Orion collaborate on next-generation drug development

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform's award-winning CESS® technology to new chemical entities. Building on an existing relationship, this collaboration will utilize Nanoform’s proprietary CESS® technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development. Many new chemical entities struggle to progress into clinical development due to

The trade in Stayble’s shares and warrants on Nasdaq First North Growth Markets commences today

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North Growth Market. The share is traded under the ticker “STABL” with the ISIN code SE0013513652 and the warrant is traded under the ticker ”STABL TO1” with the ISIN code SE0013748381.New units issue prior to listing The Company’s new issue of SEK 35 million was, in the beginning of 2020, subscribed to approximately SEK 153 million (corresponding to a subscription rate of 436%) and the Company will receive around 830 new shareholders.

Electrolux issues bond loans

Electrolux today issued two bond loans in the aggregate amount of SEK 3.0 billion under its EMTN (Euro Medium Term Note) programme.Two bond loans are issued on March 9, 2020 with maturity on March 9, 2022. One of the bond loans, in the amount of SEK 250 million, is issued at a fixed rate and carries a coupon of 0.405% annually. The other bond loan, in the amount of SEK 2 750 million, has a floating interest rate. The bonds will be listed on the Luxembourg Stock Exchange. The bond proceeds will be used for general corporate purposes. Detailed information on the bond loans and terms of

FDA accepts protocol for new Traumakine trial

Faron Pharmaceuticals Oy ("Faron" or the "Company")   FDA accepts protocol for new Traumakine trial in ARDS       Company announcement, 09 March 2020 at 9.00 AM (EET)Inside information   TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the U.S. Food and Drug Administration (FDA) has accepted the proposed protocol design for the next Traumakine study in ARDS patients, following the Company's protocol submission announced on 6 February 2020.    The trial protocol

Neste and Mirova back Recycling Technologies to accelerate transition to circular economy for plastic

Neste Corporation, Press Release, 9 March 2020 at 9 a.m. (EET) Neste, the world’s leading provider of renewable diesel , renewable jet fuel , and an expert in delivering drop-in renewable chemical solutions , and Mirova, a pioneer impact investor in the natural capital space and an affiliate of Natixis Investment Managers, today announce a combined EUR 10 million investment into

Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™

Viken – 9th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of Locust Walk (LW) as strategic advisor and business development representative for the licensing process of ILB™.   “We are very pleased to secure this new collaboration as we have already worked closely with Locust Walk over the past twelve months, assessing our ILB™ portfolio and exploring our commercialization opportunities within different neurodegenerative disease areas such as ALS. With their proven track record and in-depth market insights in the field of

Redeye: Medicover - Fundamentally Strong, Defensive Investment

Redeye reiterates its fundamentally positive stance on Medicover and raises estimates and valuation following strong full-year 2019 results. Most importantly, we believe the top line will grow at a good pace going forward and are looking for organic growth of +14% per year. As the successful Indian acquisition will be fully consolidated this year, 2020 revenues are likely to jump an impressive 33% surpassing EUR 1bn. We also highlight the defensive qualities of the Medicover case in the current market environment and look at Medicover’s various locations in India, the Indian economy and

Panoro Energy Starts Oil Production from the second Tortue Phase 2 well, offshore Gabon

Oslo, 9 March 2020 - Panoro Energy (the “Company” or “Panoro” with OSE ticker: “PEN”) is pleased to announce the commencement of oil production from the DTM-4H well, the second in the cluster of two wells brought online within the Tortue Phase 2 field development project in the Dussafu Marin Permit, offshore Gabon. The first well DTM-5H started producing last week, as announced on 5 March 2020. Following the addition of the two wells, the overall field production continues to stabilise, with current output at approximately 20.0 kbopd gross. The Tortue Phase 2 development consists of four

Axactor acquires another paying portfolio from large Italian Financial Institution

Oslo, March 9th 2020 Axactor has successfully acquired another portfolio of payment plans secured against promissory notes. This portfolio is from the same seller as the portfolio acquired in Q4 2020. This portfolio contains circa 3.000 claims with an outstanding balance of approximately 25mEur. The sale will close in March.  “This acquisition demonstrates Axactor’s clear focus on delivering revenue growth in 2020 and we are pleased to deliver it from an existing client.” says Antonio Cataneo, Axactor Italy Country Manager Germany.              This investment will be financed by

Amuse Introduces Amuse Pro - For the Growing Sector of Independent Artists, Collectives, Labels and Managers

Offers upgraded features for the independent music sector, which grew by 25% in revenue in 2019. Amuse, the reimagined record label giving free music distribution and empowering tools to artists across the globe, today announces the launch of Amuse Pro, a new tier of their digital music distribution service. Amuse Pro is an open subscription service offering more functionality to help artists and their teams grow their careers independently.Amuse Pro complements Amuse’s free distribution service by providing technology-driven solutions to a growing set of needs among independent artists

Positive results from follow-up of 30 patients in a Swedish multi-centre clinical trial of the Episealer® Knee implant

Episurf Medical (Nasdaq: EPIS B) today announces that results from a clinical study with follow-up of the 30 first patients from nine Swedish clinics show good implant safety and significantly improved patient-reported outcome scores. Follow-ups of the patients are now completed, and the principle investigator will compile the results for submission to a scientific journal. In total, 30 patients are included in the study and the average follow-up time is 55 months (24 – 86 months). The Episealer® Knee implant is intended for treatment of focal cartilage and osteochondral defects on the

NRC Group ASA - Cancellation of subsequent repair offering

References is made to the stock exchange notice on 12 February 2020, regarding the contemplated private placement and a potential subsequent repair offering in NRC Group ASA (“the Company”). Since the announcement of the private placement, the Company's shares have traded similar to or below the subscription price in the private placement of NOK 37. In the period from 12 February 2020 to 6 March 2020 the volume-weighted average share price (VWAP) has been NOK 33, and at the lowest the share price was NOK 26.10, approximately 29.46 percent below the subscription price. Furthermore, 4.73

BAKKAFROST: Correction of dates in the announcement 491969 made earlier today

Reference is made to the announcement (id 491969) from P/F Bakkafrost on 8 March 2020 In the referenced announcement the storm is said to have occured 28 February 2019 to 2 March 2019. This is incorrect - the correct dates are 28 February 2020 to 2 March 2020.   Contacts: · Regin Jacobsen, CEO of P/F Bakkafrost: +298 23 50 01 (mobile) · Høgni Dahl Jakobsen, CFO of P/F Bakkafrost: +298 23 50 60 (mobile)   This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading

IWD: IKEA Retail Japan CEO encourages women to do it their way

To mark International Women’s Day (IWD) on March 8 2020, Helene von Reis, Chief Executive Officer (CEO) and Chief Sustainability Officer (CSO) at IKEA Retail Japan talks about work and family life balance in the country and women receiving respect for doing it their way.IKEA Retail Japan is one of 30 operating countries for Ingka Group, a strategic partner in the IKEA franchise system. There are nine stores, one distribution, and a newly opened IKEA for Business planning studio in the country.  Ingka Group believes that everyone has the right to be treated fairly and given equal

Read original

BAKKAFROST: Severe storm hit the Faroe Islands and damaged two farming sites resulting in the loss of 1 million fish

A severe storm hit the Faroe Islands on 28 February 2019 and lasted for four days until 2 March 2019. The storm caused significant damage to two of Bakkafrost’s farming sites in the South Island (Suðuroy): A23 Hvalba and A15 Froðba. The storm overstressed some of the farming equipment in A23 Hvalba and damaged the nets in 12 pens in the two farming sites. In A15 Froðba a continuous ground swell over 5 days caused significant mortality of the fish. In total Bakkafrost lost around 1 million fish with an average weight of 2.1 kg. The farming equipment is insured and the fish is

Hungary in the lead when it comes to female leadership

Hungary, Croatia and Sweden is the three leading countries in Europe when it comes to female business leadership, according to the Bisnode Index of Women Influence (BiWi). BiWi measures the share of companies that have a female owner, CEO or chairman of the board."Women’s participation in both ownership and governance issues are becoming increasingly important, not only for the individual company but for the economy as a whole. BiWi is a unique and important comparison of countries according to the influence women have on their economies", says Anna Albinsson, Chief Marketing Officer

Notice of Extraordinary General Meeting in Swedish Stirling AB (publ)

The shareholders of Swedish Stirling AB (publ) are hereby invited to attend the Extraordinary General Meeting (“EGM”) to be held at 9.30 a.m. CET on Wednesday, 8 April 2020 at Mannheimer Swartling Advokatbyrå, Östra Hamngatan 16, Gothenburg. Registration will commence at 9.00 a.m. CET.A. RIGHT TO ATTEND THE EXTRAORDINARY GENERAL MEETING Shareholders who wish to attend the EGM shall: firstly, be registered in the share register maintained by Euroclear Sweden AB as of Thursday, 2 April 2020, and secondly, preferably notify the company of their intention to attend the EGM under the

There are no items matching the current filter
There are no more items matching the current filter
Back to top